Many over 50s seem to be asking this question. But there are a number of reasons it’s important to go ahead and get the AstraZeneca vaccine now.
Articles on AstraZeneca vaccine
Displaying 41 - 60 of 156 articles
What does the Seychelles experience tell us about variants, vaccine efficacy and herd immunity?
Research has shown that vaccines have reduced infections, disease and hospitalisations – but will they continue to do so in the face of new variants?
The TGA has reported a handful of cases of the autoimmune disorder Guillain-Barré syndrome following the AstraZeneca vaccine.
This week’s budget assumes all Australians will have the chance to be fully vaccinated by the end of the year. It’s ambitious but possible.
Public officials are telling us simultaneously to move swiftly on vaccination and also to make thoughtful, reasoned choices about which vaccine we get. These messages are confusing and frustrating.
You only have to prevent one case, which could have otherwise led to community spread and lockdown, for such a scheme to pay for itself many times over.
Canadian public health organizations have run into a serious communication problem about the AstraZeneca vaccine. Crisis management and communication theories explain what’s gone wrong.
Vaccination is likely to substantially reduce virus transmission by reducing the pool of people who become infected, and reducing virus levels in people who do get infected.
The AstraZeneca COVID vaccine is now available to Australians over 50. Here’s what you need to know before you roll up your sleeve.
The COVID-19 vaccination programme requires stringent data collection and transparency.
Licensing agreements between pharmaceutical companies and the Medicines Patent Pool, in cooperation with the WHO, could accelerate access to doses for the poorest countries.
The R21 vaccine protected three-quarters of children against malaria in trials.
Britain moves to protect itself from the B1617 variant, which vaccines may be less effective against.
Current assessments of the risk of blood clots are still uncertain.
Side effects generally indicate a natural immune response and will resolve in a few days.
Australia was promised a world-class vaccine program. But instead of a rollout, we got an eekout.
The amount of risk from overseas arrivals depends not just on Australia’s vaccination rates, but also on the particular circumstances of the country from which people are travelling.
Both the AstraZeneca and Johnson & Johnson vaccines are now being investigated for links to rare blood disorders.
India and South Africa are pressing the World Trade Organization to waive patent rights to help ramp up vaccine production. There’s a better solution.
Top contributors
-
Professorial Fellow, University of Canberra
-
Senior Research Fellow in Global Health, University of Southampton
-
Vice-Chancellor's Research Fellow, School of Health and Biomedical Sciences, RMIT University
-
Professor of Medicine, University of East Anglia
-
Professor of Health Service Operations, School of Pharmacy & Medical Sciences, University of Bradford
-
Professor, School of Biomedical Sciences and Pharmacy, University of Newcastle
-
Professor, The Children's Hospital at Westmead Clinical School and Sydney Infectious Diseases Institute, University of Sydney
-
Deputy Director of the HUMLOG (Humanitarian Logistics and Supply Chain Management Research) Institute, Hanken School of Economics
-
Distinguished Professor, Professor of Immunology, RMIT University
-
General Practitioner, PhD Candidate, Bond University
-
Professor of Immunology, RMIT University
-
Chair in Epidemiology, Deakin University
-
Principal Lecturer, Microbiology and Biomedical Science Practice, Fellow of the Institute of Biomedical Science, University of Brighton
-
Professor of Intellectual Property Law, Queen Mary University of London
-
Postdoctoral Research Fellow, RMIT University